CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products...
Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of...
Bioxytran, Inc. (OTCMKTS: BIXT) (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced...
Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects...
Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with...
On February 6, Distinct Healthcare Holdings Limited (Distinct Healthcare or the Company, Stock Code: 2677.HK), a leading player in China's mid-to-high-end consumer healthcare services...
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
